Karyopharm downgraded to Neutral from Buy at H.C. Wainwright

H.C. Wainwright analyst Robert Burns downgraded Karyopharm (KPTI) to Neutral from Buy without a price target The firm has solvency concerns, saying the company’s recent failure to raise capital raise is a “significant concern.” H.C. Wainwright also also takes into account that the top-line results from the Phase 3 trial evaluating selinexor in JAKi-naive myelofibrosis are not expected until Q1 of 2026.